Total Payments
$2,253
2024 Payments
$109.92
Companies
20
Transactions
104
Medicare Patients
2,739
Medicare Billing
$244,585
Payment Breakdown by Category
Food & Beverage$2,202 (97.7%)
Education$51.21 (2.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,202 | 99 | 97.7% |
| Education | $51.21 | 5 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $703.55 | 34 | $0 (2019) |
| Janssen Biotech, Inc. | $409.21 | 17 | $0 (2019) |
| PROGENICS PHARMACEUTICALS, INC. | $109.92 | 1 | $0 (2024) |
| AbbVie, Inc. | $101.24 | 7 | $0 (2018) |
| Boston Scientific Corporation | $96.20 | 2 | $0 (2019) |
| Endo Pharmaceuticals Inc. | $93.91 | 5 | $0 (2019) |
| Coloplast Corp | $91.82 | 4 | $0 (2018) |
| NeoTract Inc. | $81.52 | 1 | $0 (2019) |
| Dendreon Pharmaceuticals LLC | $80.45 | 4 | $0 (2019) |
| PFIZER INC. | $79.23 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $109.92 | 1 | PROGENICS PHARMACEUTICALS, INC. ($109.92) |
| 2020 | $14.71 | 1 | Medtronic Vascular, Inc. ($14.71) |
| 2019 | $494.17 | 17 | Astellas Pharma US Inc ($168.46) |
| 2018 | $731.31 | 39 | Astellas Pharma US Inc ($252.82) |
| 2017 | $902.90 | 46 | Astellas Pharma US Inc ($282.27) |
All Payment Transactions
104 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/16/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $109.92 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 01/10/2020 | Medtronic Vascular, Inc. | Azure (Device) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: Pacemakers | ||||||
| 12/13/2019 | Boston Scientific Corporation | GENERAL THERAPIES (Device) | Food and Beverage | In-kind items and services | $80.17 | General |
| Category: THERAPIES | ||||||
| 12/06/2019 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $93.51 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $45.56 | General |
| Category: Oncology | ||||||
| 04/25/2019 | NeoTract Inc. | UroLift (Device) | Food and Beverage | In-kind items and services | $81.52 | General |
| Category: Interventional Urology | ||||||
| 03/29/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: Oncology | ||||||
| 03/13/2019 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 03/11/2019 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2019 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $7.56 | General |
| Category: UROLOGY | ||||||
| 02/25/2019 | Ferring Pharmaceuticals Inc. | FIRMAGON (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: UROLOGY | ||||||
| 02/18/2019 | Endo Pharmaceuticals Inc. | AVEED (Biological), XIAFLEX | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: UROLOGY | ||||||
| 02/14/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: Oncology | ||||||
| 02/04/2019 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: ONCOLOGY | ||||||
| 02/04/2019 | Astellas Pharma US Inc | XTANDI (Drug) | Education | In-kind items and services | $7.78 | General |
| Category: ONCOLOGY | ||||||
| 01/21/2019 | Blue Earth Diagnostics Limited | Axumin (Drug) | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Diagnostic Imaging | ||||||
| 01/17/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $11.19 | General |
| Category: Oncology | ||||||
| 01/14/2019 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2019 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $9.10 | General |
| Category: UROLOGY | ||||||
| 12/17/2018 | Coloplast Corp | SPEEDICATH (Device) | Education | Cash or cash equivalent | $10.72 | General |
| Category: CONTINENCE | ||||||
| 12/10/2018 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2018 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Oncology | ||||||
| 11/26/2018 | Avadel Specialty Pharmaceuticals, LLC | Noctiva (Drug) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: Urology | ||||||
| 10/29/2018 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2018 | Boston Scientific Corporation | GENERAL BPH (Device) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: BPH | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 591 | 733 | $210,400 | $59,469 |
| 2022 | 7 | 576 | 739 | $240,380 | $65,269 |
| 2021 | 7 | 782 | 895 | $235,222 | $61,676 |
| 2020 | 9 | 790 | 1,065 | $269,642 | $58,171 |
Total Patients
2,739
Total Services
3,432
Medicare Billing
$244,585
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 232 | 312 | $83,616 | $30,152 | 36.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 229 | 282 | $51,324 | $18,242 | 35.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 50 | 50 | $13,600 | $4,395 | 32.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $10,790 | $3,507 | 32.5% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 43 | 50 | $42,750 | $2,914 | 6.8% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 11 | 13 | $8,320 | $257.27 | 3.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 213 | 301 | $80,668 | $28,261 | 35.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 226 | 292 | $53,144 | $19,879 | 37.4% |
| 52601 | Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | Facility | 2022 | 11 | 11 | $36,388 | $6,443 | 17.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 44 | 44 | $11,968 | $3,439 | 28.7% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 44 | 53 | $45,315 | $3,387 | 7.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 21 | 21 | $8,715 | $2,706 | 31.0% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 17 | 17 | $4,182 | $1,154 | 27.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 190 | 211 | $38,402 | $16,059 | 41.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 103 | 109 | $29,212 | $11,928 | 40.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 205 | 230 | $41,860 | $10,818 | 25.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 129 | 155 | $41,540 | $9,615 | 23.1% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Facility | 2021 | 46 | 58 | $49,590 | $3,599 | 7.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 31 | 31 | $7,938 | $2,535 | 31.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 42 | $8,058 | $2,525 | 31.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 18 | 18 | $7,470 | $1,939 | 26.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 17 | 17 | $4,624 | $1,518 | 32.8% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 24 | 24 | $6,528 | $1,138 | 17.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 308 | 454 | $121,672 | $29,430 | 24.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 217 | 278 | $50,596 | $8,026 | 15.9% |
About Dr. Erik Enquist, MD
Dr. Erik Enquist, MD is a Urology healthcare provider based in Westerly, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1619963535.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Erik Enquist, MD has received a total of $2,253 in payments from pharmaceutical and medical device companies, with $109.92 received in 2024. These payments were reported across 104 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($2,202).
As a Medicare-enrolled provider, Enquist has provided services to 2,739 Medicare beneficiaries, totaling 3,432 services with total Medicare billing of $244,585. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Urology
- Location Westerly, RI
- Active Since 09/26/2005
- Last Updated 04/25/2008
- Taxonomy Code 208800000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1619963535
Products in Payments
- XTANDI (Drug) $312.92
- Erleada (Drug) $209.48
- ZYTIGA (Drug) $208.32
- PROVENGE (Drug) $159.22
- MYRBETRIQ (Drug) $152.17
- Myrbetriq (Drug) $131.28
- PYLARIFY (Drug) $109.92
- UroLift (Device) $81.52
- GENERAL THERAPIES (Device) $80.17
- XIAFLEX (Biological) $77.90
- Lupron (Drug) $66.82
- Xtandi (Drug) $62.30
- ELIGARD (Drug) $57.46
- PENILE RECONSTRUCTION (Device) $56.98
- FIRMAGON (Drug) $52.72
- Noctiva (Drug) $52.37
- SPEEDICATH (Device) $48.83
- Axumin (Drug) $48.77
- Androgel (Drug) $34.42
- Urgent PC (Device) $30.98
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.